A Multicentre, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer
The study will investigate the efficacy, pharmacokinetics and safety of two subcutaneous
injections of triptorelin embonate 22.5 mg 6-month formulation in patients with prostate
cancer. The total duration of the study per patient will be 12 months (48 weeks)
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary Efficacy
Percentage of patients achieving castrate levels of serum testosterone (< 1.735 nmol/L) by Day 29. Percentage of patients maintaining castrate levels of serum testosterone (< 1.735 nmol/L) from Month 2 (Day 57) to end of Month 12 (Day 337).
Month 1 (Day 29) and from Month 2 (Day 57) to end of Month 12 (Day 337)
No
Eija Lundstrom, MD
Study Director
Debiopharm SA
South Africa: Medicines Control Council
Debio 8206-SC-301
NCT01656161
July 2012
November 2013
Name | Location |
---|